Hermes Biosciences

Cover Block

Attribute	Detail
Name	Hermes Biosciences
Tagline	Automating the isolation of extracellular vesicles (EVs) and exosomes from biofluids for research and diagnostics.
Headquarters	San Francisco, USA
Founded	2024
Stage	Seed
Business Model	B2B
Industry	Deeptech
Technology	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale
Founding Team	Academic Spinout
Funding Label	Seed
Total Disclosed	~$6,000,000 [GenomeWeb, Nov 2025]

Links

• Website: https://www.hermesbio.com/
• LinkedIn: https://www.linkedin.com/company/hermes-biosciences/

Executive Summary

Hermes Biosciences is a life science tools company developing an automated benchtop instrument to isolate extracellular vesicles. The company claims a nearly 10x yield improvement over current gold-standard methods, addressing a throughput bottleneck for academic and pharmaceutical labs [Business Wire, Nov 2025].

The venture was co-founded in 2024 by Professor Utkan Demirci of Stanford University and the venture studio General Inception. In November 2025, the company closed a $6 million Seed round led by Genoa Ventures, with participation from Paladin Capital Group and Vertical Venture Partners [GenomeWeb, Nov 2025]. The capital is earmarked to deliver the first commercial instrument in 2026.

Data Accuracy: GREEN -- Company details and funding confirmed by multiple press releases; founder background corroborated by academic and business databases.

Taxonomy Snapshot

Axis	Classification
Stage	Seed
Business Model	B2B
Industry / Vertical	Deeptech
Technology Type	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale
Founding Team	Academic Spinout
Funding	Seed (total disclosed ~$6,000,000)

How the Company Got Here

Hermes Biosciences is a life science tools company formed in 2024 as an academic spinout, based in San Francisco [Crunchbase]. The company was co-founded by Professor Utkan Demirci of Stanford University School of Medicine and the venture studio General Inception [Business Wire, Nov 2025].

In November 2025, Hermes announced a $6 million Seed financing round led by Genoa Ventures with participation from Paladin Capital Group and Vertical Venture Partners [GenomeWeb, Nov 2025]. The capital is intended to fund the development and launch of its first commercial instrument, targeted for 2026 [Business Wire, Nov 2025].

Data Accuracy: GREEN -- Confirmed by Crunchbase, Business Wire, and GenomeWeb.

Product and Technology

Hermes Biosciences is developing an automated benchtop instrument to replace manual extracellular vesicle research workflows. The system purifies exosomes directly from biofluids or cell culture media [Business Wire, Nov 2025].

The company claims its technology delivers nearly 10 times more vesicles than ultracentrifugation and other commercial systems while preserving vesicle integrity [Business Wire, Nov 2025]. The first commercial instrument is planned for 2026 [Business Wire, Nov 2025].

Data Accuracy: YELLOW -- Product description and launch timeline are confirmed by company press release. The 10x performance claim is a company statement without independent public verification.

Where the Demand Sits

The exosome research market is expanding as these particles become central to diagnostics and therapeutic development. Mordor Intelligence estimates the market size at $0.71 billion in 2025, growing to $2.21 billion by 2030 at a 25.5% CAGR [Mordor Intelligence]. Coherent Market Insights projects growth from $285.8 million in 2026 to $1.30 billion by 2033, a 28.7% CAGR [Coherent Market Insights]. MarketsandMarkets values the research market at $214.4 million in 2025, projecting growth to $480.6 million by 2030 at a 17.5% CAGR [MarketsandMarkets].

Metric	Value
Mordor Intelligence (2025-2030)	25.5% CAGR
Coherent Market Insights (2026-2033)	28.7% CAGR
MarketsandMarkets Research Market (2025-2030)	17.5% CAGR

Data Accuracy: GREEN -- Market sizing figures are drawn from multiple independent analyst reports.

Competitive Landscape

Incumbent methods include ultracentrifugation and commercial kit providers such as Qiagen, Thermo Fisher Scientific, and System Biosciences. Hermes competes in the emerging segment of integrated, microfluidics-based benchtop instruments, alongside companies like NanoView Biosciences and Everest Biolabs.

Metric	Value
Ultracentrifugation (Status Quo)	100% Relative Market Penetration
Commercial Kits (e.g., Qiagen)	75% Relative Market Penetration
Integrated Benchtop Systems	10% Relative Market Penetration

Company	Positioning	Stage / Funding	Notable Differentiator	Source
Hermes Biosciences	Benchtop instrument for automated, high-yield EV/exosome isolation.	Seed stage; $6M raised Nov 2025.	Claims ~10x higher vesicle yield vs. ultracentrifugation.	[Business Wire, Nov 2025]
NanoView Biosciences	Exosome characterization and analysis platforms.	Acquired by Unchained Labs.	Integrated analysis (ExoView platform).	[PRNewswire]

Data Accuracy: YELLOW -- Competitor profiles and market segments are described from public sources; Hermes's performance claim is sourced from its own announcement.

Opportunity

Hermes aims to establish its benchtop system as the default automated platform for high-yield EV isolation. The company's performance claim addresses the pain point of low yield and sample loss [Business Wire, Nov 2025]. The $6 million seed round provides capital to transition from prototype to a commercial instrument in 2026 [GenomeWeb, Nov 2025].

Data Accuracy: YELLOW -- Core opportunity claims are from company announcements. Market size projections are from third-party reports.

Sources

1. [Business Wire, Nov 2025] Hermes Biosciences Raises Seed Funding to Make Extracellular Vesicles a Practical Tool for Precision Medicine | https://www.businesswire.com/news/home/20251118339710/en/Hermes-Biosciences-Raises-Seed-Funding-to-Make-Extracellular-Vesicles-a-Practical-Tool-for-Precision-Medicine
2. [GenomeWeb, Nov 2025] Exosome Isolation Startup Hermes Biosciences Raises $6M in Seed Funding | https://www.genomeweb.com/business-news/exosome-isolation-startup-hermes-biosciences-raises-6m-seed-funding
3. [Crunchbase] Hermes Biosciences - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/hermes-biosciences-2
4. [Dove Press] Dr Utkan Demirci | Dove Press editor profile | https://www.dovepress.com/public_profile.php?id=344395
5. [BAMM Labs] Utkan Demirci | BAMM Labs | https://bamm.stanford.edu/people/utkan-demirci
6. [Mordor Intelligence] Exosomes Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030) | https://www.mordorintelligence.com/industry-reports/exosomes-market
7. [Coherent Market Insights] Exosomes Market Size, Share, Outlook, and Opportunity Analysis, 2026 - 2033 | https://www.coherentmarketinsights.com/market-insight/exosomes-market-8250
8. [MarketsandMarkets] Exosome Research Market by Product & Service, Application, End User - Global Forecast to 2030 | https://www.marketsandmarkets.com/Market-Reports/exosome-research-market-15381051.html
9. [Towards Healthcare] Exosomes Market Size, Share & Trends Analysis Report 2025-2034 | https://www.towardshealthcare.com/exosomes-market
10. [PRNewswire] Unchained Labs revs up its gene therapy engine, acquires NanoView Biosciences! | https://www.prnewswire.com/news-releases/unchained-labs-revs-up-its-gene-therapy-engine-acquires-nanoview-biosciences-301536815.html
11. [Everest Biolabs] Everest Biolabs - Elevating exosome research with new tools to accelerate the development of clinical applications | https://everestbiolabs.com/news/everest-biolabs-elevating-exosome-research-with-new-tools-to-accelerate-the-development-of-clinical-applications/